Login Register Cart 0
Generic placeholder image

Current Pediatric Reviews

Editor-in-Chief

ISSN (Print): 1573-3963
ISSN (Online): 1875-6336

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Recent Insights into COVID-19 in Children and Clinical Recommendations

Author(s): Jairo Castellar-López, Wendy Villamizar-Villamizar, Aldo Amaranto-Pallares, Wendy Rosales-Rada, Maria De Los Angeles Vélez Verbel, Aileen Chang, Franklin Torres Jiménez and Evelyn Mendoza-Torres*

Volume 18, Issue 2, 2022

Published on: 29 December, 2021

Page: [121 - 137] Pages: 17

DOI: 10.2174/1573396317666211206124347

Price: $65

Abstract

Pediatric coronavirus disease 2019 (COVID-19) and multisystem inflammatory syndrome in children (MIS-C) have been recognized in multiple countries globally. In this review, we provide recent insights into SARS-CoV-2 infection in children from epidemiological, clinical, and laboratory perspectives, including reports on the disease course and therapy. We highlight key features of SARS-CoV-2 infection in children, the relationship between MIS-C and Kawasaki disease, and summarize treatment guidelines for COVID-19 in children from institutional protocols from Colombia, case reports, recommendations based on expert consensus, and official statements from organizations such as the World Health Organization (WHO), United States Center for Disease Control (CDC), Colombian Association of Infectious Diseases, and the Colombian Society of Pediatrics. Finally, we discuss gaps in research with suggestions for future research on the pathogenesis underlying pediatric COVID-19.

Keywords: COVID-19, SARS-CoV-2, kawasaki disease, inflammation, multisystem inflammatory syndrome, children.

« Previous Next »
Graphical Abstract

[1]
Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics 2020; 145(6): e20200702.
[http://dx.doi.org/10.1542/peds.2020-0702] [PMID: 32179660]
[2]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[3]
Sungnak W, Huang N, Bécavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med 2020; 26(5): 681-7.
[http://dx.doi.org/10.1038/s41591-020-0868-6] [PMID: 32327758]
[4]
Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020; 20(5): 533-4.
[http://dx.doi.org/10.1016/S1473-3099(20)30120-1] [PMID: 32087114]
[5]
Bixler D, Miller AD, Mattison CP, et al. SARS-CoV-2-Associated Deaths Among Persons Aged <21 Years - United States, February 12-July 31, 2020. MMWR Morb Mortal Wkly Rep 2020; 69(37): 1324-9.
[http://dx.doi.org/10.15585/mmwr.mm6937e4] [PMID: 32941417]
[6]
D’Amico F, Baumgart DC, Danese S, Peyrin-Biroulet L. Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention, and management. Clin Gastroenterol Hepatol 2020; 18(8): 1663-72.
[http://dx.doi.org/10.1016/j.cgh.2020.04.001] [PMID: 32278065]
[7]
Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther 2020; 51(9): 843-51.
[http://dx.doi.org/10.1111/apt.15731] [PMID: 32222988]
[8]
Hasan MR, Al Zubaidi K, Diab K, et al. COVID-19 related multisystem inflammatory syndrome in children (MIS-C): a case series from a tertiary care pediatric hospital in Qatar. BMC Pediatr 2021; 21(1): 267.
[http://dx.doi.org/10.1186/s12887-021-02743-8] [PMID: 34103044]
[9]
Deza Leon MP, Redzepi A, McGrath E, et al. COVID-19-associated pediatric multisystem inflammatory syndrome. J Pediatric Infect Dis Soc 2020; 9(3): 407-8.
[http://dx.doi.org/10.1093/jpids/piaa061] [PMID: 32441749]
[10]
Hennon TR, Penque MD, Abdul-Aziz R, et al. COVID-19 associated Multisystem Inflammatory Syndrome in Children (MIS-C) guidelines; a Western New York approach. Prog Pediatr Cardiol 2020; 57: 101232.
[http://dx.doi.org/10.1016/j.ppedcard.2020.101232] [PMID: 32837142]
[11]
Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 2020; 395(10239): 1771-8.
[http://dx.doi.org/10.1016/S0140-6736(20)31103-X] [PMID: 32410760]
[12]
Newburger JW, Takahashi M, Burns JC. Kawasaki Disease. J Am Coll Cardiol 2016; 67(14): 1738-49.
[http://dx.doi.org/10.1016/j.jacc.2015.12.073] [PMID: 27056781]
[13]
Bialek S, Boundy E, Bowen V, et al. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep 2020; 69(12): 343-6.
[http://dx.doi.org/10.15585/mmwr.mm6912e2] [PMID: 32214079]
[14]
Turnier JL, Anderson MS, Heizer HR, Jone P-N, Glodé MP, Dominguez SR. Concurrent respiratory viruses and Kawasaki Disease. Pediatrics 2015; 136(3): e609-14.
[http://dx.doi.org/10.1542/peds.2015-0950] [PMID: 26304824]
[15]
Roe K. A viral infection explanation for Kawasaki disease in general and for COVID-19 virus-related Kawasaki disease symptoms. Inflammopharmacology 2020; 28(5): 1219-22.
[http://dx.doi.org/10.1007/s10787-020-00739-x] [PMID: 32638151]
[16]
Pouletty M, Borocco C, Ouldali N, et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Ann Rheum Dis 2020; 79(8): 999-1006.
[http://dx.doi.org/10.1136/annrheumdis-2020-217960] [PMID: 32527868]
[17]
Geng Y-J, Wei Z-Y, Qian H-Y, Huang J, Lodato R, Castriotta RJ. Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019. Cardiovasc Pathol 2020; 47: 107228.
[http://dx.doi.org/10.1016/j.carpath.2020.107228] [PMID: 32375085]
[18]
Zhang Y, Zeng X, Jiao Y, et al. Mechanisms involved in the development of thrombocytopenia in patients with COVID-19. Thromb Res 2020; 193: 110-5.
[http://dx.doi.org/10.1016/j.thromres.2020.06.008] [PMID: 32535232]
[19]
Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol 2020; 215: 108427.
[http://dx.doi.org/10.1016/j.clim.2020.108427] [PMID: 32325252]
[20]
Hosoki K, Chakraborty A, Sur S. Molecular mechanisms and epidemiology of COVID-19 from an allergist’s perspective. J Allergy Clin Immunol 2020; 146(2): 285-99.
[http://dx.doi.org/10.1016/j.jaci.2020.05.033] [PMID: 32624257]
[21]
Mihalopoulos M, Dogra N, Mohamed N, Badani K, Kyprianou N. COVID-19 and kidney disease: molecular determinants and clinical implications in renal cancer. Eur Urol Focus 2020; 6(5): 1086-96.
[http://dx.doi.org/10.1016/j.euf.2020.06.002] [PMID: 32540268]
[22]
Patel AB, Verma A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence? JAMA 2020; 323(18): 1769-70.
[http://dx.doi.org/10.1001/jama.2020.4812] [PMID: 32208485]
[23]
Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203(2): 631-7.
[http://dx.doi.org/10.1002/path.1570] [PMID: 15141377]
[24]
Castagnoli R, Votto M, Licari A, et al. Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection in children and adolescents: a systematic review. JAMA Pediatr 2020; 174(9): 882-9.
[http://dx.doi.org/10.1001/jamapediatrics.2020.1467] [PMID: 32320004]
[25]
Bunyavanich S, Do A, Vicencio A. Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. JAMA 2020; 323(23): 2427-9.
[http://dx.doi.org/10.1001/jama.2020.8707] [PMID: 32432657]
[26]
Siripanthong B, Nazarian S, Muser D, et al. Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management. Heart Rhythm 2020; 17(9): 1463-71.
[http://dx.doi.org/10.1016/j.hrthm.2020.05.001] [PMID: 32387246]
[27]
Ong EZ, Chan YFZ, Leong WY, et al. A dynamic immune response shapes COVID-19 progression. Cell Host Microbe 2020; 27(6): 879-882.e2.
[http://dx.doi.org/10.1016/j.chom.2020.03.021] [PMID: 32359396]
[28]
Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev 2020; 53: 25-32.
[http://dx.doi.org/10.1016/j.cytogfr.2020.05.003] [PMID: 32446778]
[29]
Velazquez-Salinas L, Verdugo-Rodriguez A, Rodriguez LL, Borca MV. The role of interleukin 6 during viral infections. Front Microbiol 2019; 10: 1057.
[http://dx.doi.org/10.3389/fmicb.2019.01057] [PMID: 31134045]
[30]
Shekhawat J, Gauba K, Gupta S, et al. Interleukin-6 perpetrator of the COVID-19 cytokine storm. Indian J Clin Biochem 2021; 1-11.
[PMID: 34177139]
[31]
van Nieuwkoop C. COVID-19 associated pulmonary thrombosis. Thromb Res 2020; 191: 151.
[http://dx.doi.org/10.1016/j.thromres.2020.04.042] [PMID: 32386985]
[32]
Ruscitti P, Berardicurti O, Iagnocco A, Giacomelli R. Cytokine storm syndrome in severe COVID-19. Autoimmun Rev 2020; 19(7): 102562.
[http://dx.doi.org/10.1016/j.autrev.2020.102562] [PMID: 32376400]
[33]
Mahase E. Covid-19: Cases of inflammatory syndrome in children surge after urgent alert. BMJ 2020; 369: m1990.
[http://dx.doi.org/10.1136/bmj.m1990] [PMID: 32414749]
[34]
Waltuch T, Gill P, Zinns LE, et al. Features of COVID-19 post-infectious cytokine release syndrome in children presenting to the emergency department. Am J Emerg Med 2020; 38(10): 2246.e3-6.
[http://dx.doi.org/10.1016/j.ajem.2020.05.058] [PMID: 32471782]
[35]
Ramírez PLR, del Grajales MA, Zárate Morales CA, Cuatecontzi RA, Carrasco CA. Enfermedad De Kawasaki y SARS-CoV-2, Reporte De Un Caso. Alergia. Asma e Inmunología Pediátricas 2020; 29(2): 52-8.
[http://dx.doi.org/10.35366/95490]
[36]
Alizargar J. The novel coronavirus (COVID-19) and the risk of Kawasaki disease in children. J Formos Med Assoc 2020; 119(11): 1713-4.
[http://dx.doi.org/10.1016/j.jfma.2020.05.030] [PMID: 32456973]
[37]
Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med 2020; 383(4): 334-46.
[http://dx.doi.org/10.1056/NEJMoa2021680] [PMID: 32598831]
[38]
Jones VG, Mills M, Suarez D, et al. COVID-19 and Kawasaki Disease: novel virus and novel case. Hosp Pediatr 2020; 10(6): 537-40.
[http://dx.doi.org/10.1542/hpeds.2020-0123] [PMID: 32265235]
[39]
Loomba RS, Villarreal E, Flores S. COVID-19 and Kawasaki syndrome: should we really be surprised? Cardiol Young 2020; 30(7): 1059-60.
[http://dx.doi.org/10.1017/S1047951120001432] [PMID: 32412400]
[40]
Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020; 395(10237): 1607-8.
[http://dx.doi.org/10.1016/S0140-6736(20)31094-1] [PMID: 32386565]
[41]
Panupattanapong S, Brooks EB. New spectrum of COVID-19 manifestations in children: Kawasaki-like syndrome and hyperinflammatory response. Cleve Clin J Med 2020.
[http://dx.doi.org/10.3949/ccjm.87a.ccc039] [PMID: 32493734]
[42]
Panamericana de la Salud / World Organization of Health. Epidemiological update: Coronavirus infection (COVID-19) January 15, 2021. Washington, D.C: PAHO / WHO 2021.
[43]
Kebudi R, Kurucu N, Tuğcu D, et al. COVID-19 infection in children with cancer and stem cell transplant recipients in Turkey: A nationwide study. Pediatr Blood Cancer 2021; 68(6): e28915.
[http://dx.doi.org/10.1002/pbc.28915] [PMID: 33538100]
[44]
Sullivan M, Bouffet E, Rodriguez-Galindo C, et al. The COVID-19 pandemic: A rapid global response for children with cancer from SIOP, COG, SIOP-E, SIOP-PODC, IPSO, PROS, CCI, and St Jude Global. Pediatr Blood Cancer 2020; 67(7): e28409.
[http://dx.doi.org/10.1002/pbc.28409] [PMID: 32400924]
[45]
Kebudi R, Chantada G, Kurucu N, Tugcu D, Mukkada S, Moreira DC. COVID-19: consequences for children with cancer in turkey and globally. Turk Pediatri Ars 2021; 56(4): 295-9.
[http://dx.doi.org/10.5152/TurkArchPediatr.2021.21134]
[46]
Schroeder AR, Wilson KM, Ralston SL. COVID-19 and Kawasaki Disease: Finding the signal in the noise. Hosp Pediatr 2020; 10(10): e1-3.
[PMID: 32404331]
[47]
Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol 2020; 75(18): 2352-71.
[http://dx.doi.org/10.1016/j.jacc.2020.03.031] [PMID: 32201335]
[48]
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20.
[http://dx.doi.org/10.1056/NEJMoa2002032] [PMID: 32109013]
[49]
Koçak G, Ergul Y, Nişli K, et al. Evaluation and follow-up of pediatric COVID-19 in terms of cardiac involvement: A scientific statement from the Association of Turkish pediatric cardiology and pediatric cardiac surgery. Anatol J Cardiol 2020; 24(1): 13-8.
[PMID: 32628134]
[50]
Lewis D, Fisler G, Schneider J, et al. Veno-venous extracorporeal membrane oxygenation for COVID-19-associated pediatric acute respiratory distress syndrome. Perfusion 2020; 35(6): 550-3.
[http://dx.doi.org/10.1177/0267659120939757] [PMID: 32643551]
[51]
Zhu J, Wu Y. COVID-19 epidemic: clinical characteristics of patients in pediatric isolation ward. Clin Pediatr (Phila) 2020; 59(12): 1069-73.
[http://dx.doi.org/10.1177/0009922820941228] [PMID: 32646234]
[52]
Pathak EB, Salemi JL, Sobers N, Menard J, Hambleton IR. COVID-19 in children in the United States: intensive care admissions, estimated total infected, and projected numbers of severe pediatric cases in 2020. J Public Health Manag Pract 2020; 26(4): 325-33.
[http://dx.doi.org/10.1097/PHH.0000000000001190] [PMID: 32282440]
[53]
Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. N Engl J Med 2020; 382(17): 1663-5.
[http://dx.doi.org/10.1056/NEJMc2005073] [PMID: 32187458]
[54]
Toubiana J, Poirault C, Corsia A, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ 2020; 369: m2094.
[http://dx.doi.org/10.1136/bmj.m2094] [PMID: 32493739]
[55]
Romani L, Chiurchiù S, Santilli V, et al. COVID-19 in Italian paediatric patients: The experience of a tertiary children’s hospital. Acta Paediatr 2020; 109(11): 2311-2.
[http://dx.doi.org/10.1111/apa.15465] [PMID: 32640088]
[56]
Bhumbra S, Malin S, Kirkpatrick L, et al. Clinical features of critical coronavirus disease 2019 in children. Pediatr Crit Care Med 2020; 21(10): e948-53.
[http://dx.doi.org/10.1097/PCC.0000000000002511] [PMID: 32639466]
[57]
Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis 2020; 20(6): 689-96.
[http://dx.doi.org/10.1016/S1473-3099(20)30198-5] [PMID: 32220650]
[58]
Su L, Ma X, Yu H, et al. The different clinical characteristics of corona virus disease cases between children and their families in China - the character of children with COVID-19. Emerg Microbes Infect 2020; 9(1): 707-13.
[http://dx.doi.org/10.1080/22221751.2020.1744483] [PMID: 32208917]
[59]
Ciuca IM. COVID-19 in children: an ample review. Risk Manag Healthc Policy 2020; 13: 661-9.
[http://dx.doi.org/10.2147/RMHP.S257180] [PMID: 32636686]
[60]
Kuiken T, Fouchier RAM, Schutten M, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 2003; 362(9380): 263-70.
[http://dx.doi.org/10.1016/S0140-6736(03)13967-0] [PMID: 12892955]
[61]
Rao S, Sandhu B. BAME children are most at risk of developing multisystem inflammatory syndrome-temporally associated with COVID-19. The Physician 2020; 6(1)
[http://dx.doi.org/10.38192/1.6.1.13]
[62]
Centers for disease control and prevention. Health department-reported cases of multisystem inflammatory syndrome in children (MIS-C) in the United States. Available from: https://www.cdc.gov/covid-data-tracker/#mis-national-surveillance
[63]
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72 314 cases from the chinese center for disease control and prevention. JAMA 2020; 323(13): 1239-42.
[http://dx.doi.org/10.1001/jama.2020.2648] [PMID: 32091533]
[64]
Livingston E, Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. JAMA 2020; 323(14): 1335.
[http://dx.doi.org/10.1001/jama.2020.4344] [PMID: 32181795]
[65]
Tagarro A, Epalza C, Santos M, et al. Screening and severity of coronavirus disease 2019 (COVID-19) in children in Madrid, Spain. JAMA Pediatr 2021; 175(3): 316.
[http://dx.doi.org/10.1001/jamapediatrics.2020.1346] [PMID: 33074306]
[66]
Velazquez-Salinas L, Zarate S, Eberl S, Gladue DP, Novella I, Borca MV. Positive selection of ORF1ab, ORF3a, and ORF8 genes drives the early evolutionary trends of SARS-CoV-2 during the 2020 COVID-19 Pandemic. Front Microbiol 2020; 11: 550674.
[http://dx.doi.org/10.3389/fmicb.2020.550674] [PMID: 33193132]
[67]
Rajah MM, Hubert M, Bishop E, et al. 1.1.7 and B.1.351 SARS-CoV-2 variants display enhanced spike-mediated fusion. BioRxiv 2021.
[http://dx.doi.org/10.1101/2021.06.11.448011]
[68]
Bolze A, Cirulli ET, Luo S, et al. Rapid Displacement of SARS-CoV-2 Variant B.1.1.7 by B.1.617.2 and P.1 in the United States. medRxiv 2021.
[http://dx.doi.org/10.1101/2021.06.20.21259195]
[69]
Mahase E. Delta variant: What is happening with transmission, hospital admissions, and restrictions? BMJ 2021; 373: n1513.
[http://dx.doi.org/10.1136/bmj.n1513] [PMID: 34130949]
[70]
Maishman E. Covid in children: 'No evidence' of increase in hospital numbers, say paediatricians. Available from: https://www.edinburghnews.scotsman.com/health/covidin-children-no-evidence-of-increase-in-hospital-numbers-say-paediatricians-3259535
[71]
Torjesen I. Covid-19: Delta variant is now UK’s most dominant strain and spreading through schools. BMJ 2021; 373: n1445.
[http://dx.doi.org/10.1136/bmj.n1445] [PMID: 34088699]
[72]
Willis KS. Coronavirus (COVID-19) Infection Survey, UK. 2021. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/4june2021#age-analysis-of-the-number-ofpeople-who-had-covid-19
[73]
American Academy of Pediatrics. Children and COVID-19: State-Level Data Report. Available from: https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/
[74]
Lee B, Raszka WV Jr. COVID-19 transmission and children: the child is not to blame. Pediatrics 2020; 146(2): e2020004879.
[http://dx.doi.org/10.1542/peds.2020-004879] [PMID: 32457212]
[75]
Qian G, Yang N, Ma AHY, et al. COVID-19 transmission within a family cluster by presymptomatic carriers in China. Clin Infect Dis 2020; 71(15): 861-2.
[http://dx.doi.org/10.1093/cid/ciaa316] [PMID: 32201889]
[76]
Stokes EK, Zambrano LD, Anderson KN, et al. coronavirus disease 2019 case surveillance - United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep 2020; 69(24): 759-65.
[http://dx.doi.org/10.15585/mmwr.mm6924e2] [PMID: 32555134]
[77]
Mehta NS, Mytton OT, Mullins EWS, et al. SARS-CoV-2 (COVID-19): what do we know about children? a systematic review. Clin Infect Dis 2020; 71(9): 2469-79.
[http://dx.doi.org/10.1093/cid/ciaa556] [PMID: 32392337]
[78]
Zachariah P, Johnson CL, Halabi KC, et al. Epidemiology, clinical features, and disease severity in patients with coronavirus disease 2019 (COVID-19) in a children’s hospital in New York City, New York. JAMA Pediatr 2020; 174(10): e202430.
[http://dx.doi.org/10.1001/jamapediatrics.2020.2430] [PMID: 32492092]
[79]
Liguoro I, Pilotto C, Bonanni M, et al. SARS-CoV-2 infection in children and newborns: a systematic review. Eur J Pediatr 2020; 179(7): 1029-46.
[http://dx.doi.org/10.1007/s00431-020-03684-7] [PMID: 32424745]
[80]
Wu H, Zhu H, Yuan C, et al. Clinical and immune features of hospitalized pediatric patients with coronavirus disease 2019 (COVID-19) in Wuhan, China. JAMA Netw Open 2020; 3(6): e2010895.
[http://dx.doi.org/10.1001/jamanetworkopen.2020.10895] [PMID: 32492165]
[81]
Stewart DJ, Hartley JC, Johnson M, Marks SD, du Pré P, Stojanovic J. Renal dysfunction in hospitalised children with COVID-19. Lancet Child Adolesc Health 2020; 4(8): e28-9.
[http://dx.doi.org/10.1016/S2352-4642(20)30178-4] [PMID: 32553126]
[82]
Ouldali N, Pouletty M, Mariani P, et al. Emergence of Kawasaki disease related to SARS-CoV-2 infection in an epicentre of the French COVID-19 epidemic: a time-series analysis. Lancet Child Adolesc Health 2020; 4(9): 662-8.
[http://dx.doi.org/10.1016/S2352-4642(20)30175-9] [PMID: 32622376]
[83]
World Health Organization. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19. Available from: https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19
[84]
DeBiasi RL, Song X, Delaney M, et al. Severe coronavirus disease-2019 in children and young adults in the Washington, DC, metropolitan region. J Pediatr 2020; 223: 199-203.e1.
[http://dx.doi.org/10.1016/j.jpeds.2020.05.007] [PMID: 32405091]
[85]
Centers for disease control and prevention. information for pediatric healthcare providers. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/pediatric-hcp.html
[86]
Consenso Colombiano De Atención, Diagnóstico y Manejo De La Infección Por SARS-CoV-2/COVID-19 En Establecimientos De Atención De La Salud: Recomendaciones Basadas En Consenso De Expertos e Informadas En La Evidencia ACIN-IETS. SEGUNDA EDICIÓN.1 De Agosto De 2020. Infectio 2020; 24(3)
[87]
World Health Organization. Clinical management of COVID-19: interim guidance. 2020. Available from: https://apps.who.int/iris/handle/10665/332196
[88]
Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious diseases society of America guidelines on the treatment and management of patients with coronavirus disease 2019 (COVID-19). Clin Infect Dis 2020.
[http://dx.doi.org/10.1093/cid/ciaa478]
[89]
Commissioner, O. of the. FDA approves first treatment for COVID-19. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19
[90]
National institute of allergy and infectious diseases (NIAID). Adaptive COVID-19 treatment trial (ACTT). Available from: https://clinicaltrials.gov/ct2/show/NCT04280705
[91]
Gilead sciences. Study to evaluate the safety and antiviral activity of remdesivir (GS-5734™) in participants with moderate coronavirus disease (COVID-19) compared to standard of care treatment. Available from: https://clinicaltrials.gov/ct2/show/NCT04292730
[92]
U.S national library of medicine. Study to evaluate the safety and antiviral activity of remdesivir (GS-5734™) in participants with severe coronavirus disease (COVID-19). Available from: https://clinicaltrials.gov/ct2/history/NCT04292899?V_3=View
[93]
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[94]
Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med 2021; 384(9): 795-807.
[http://dx.doi.org/10.1056/NEJMoa2031994] [PMID: 33306283]
[95]
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 - final report. N Engl J Med 2020; 383(19): 1813-26.
[http://dx.doi.org/10.1056/NEJMoa2007764] [PMID: 32445440]
[96]
Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe COVID-19. N Engl J Med 2020; 383(19): 1827-37.
[http://dx.doi.org/10.1056/NEJMoa2015301] [PMID: 32459919]
[97]
Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs. standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA 2020; 324(11): 1048-57.
[http://dx.doi.org/10.1001/jama.2020.16349] [PMID: 32821939]
[98]
Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395(10236): 1569-78.
[http://dx.doi.org/10.1016/S0140-6736(20)31022-9] [PMID: 32423584]
[99]
Piscoya A, Ng-Sueng LF, Parra Del Riego A, et al. Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis. PLoS One 2020; 15(12): e0243705.
[http://dx.doi.org/10.1371/journal.pone.0243705] [PMID: 33301514]
[100]
Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for COVID-19 - interim WHO solidarity trial results. N Engl J Med 2021; 384(6): 497-511.
[http://dx.doi.org/10.1056/NEJMoa2023184] [PMID: 33264556]
[101]
World Health Organization. WHO recommends against the use of remdesivir in COVID-19 patients Available from: https://www.who.int/es/news-room/feature-stories/detail/who-recommends-against-the-use-of-remdesivir-in-covid-19-patients
[102]
Adarsh Bhimraj RLM. COVID-19 Guideline, Part 1: Treatment and Management. Available from: http://www.idsociety.org/ COVID19guidelines
[103]
García-Salidoa AB, Jordi AD, Martínez-PajaresJD, et al. Spanish consensus on diagnosis, stabilization and treatment of pediatric multisystemic inflammatory syndrome linked to SARS-CoV-2 (SIM-PedS) Spanish Associt Paedia 2021; 94(2): 116.e1-116.e11.
[104]
Pedraza B, Suarez H, De-la-Hoz I, Fragoso P. Prevalencia de parásitos intestinales en niños de 2-5 años en hogares comunitarios de cartagena De Indias, Colombia. Rev Chil Nutr 2019; 46(3): 239-44.
[http://dx.doi.org/10.4067/S0717-75182019000300239]
[105]
Velavan TP, Pollard AJ, Kremsner PG. Herd immunity and vaccination of children for COVID-19. Int J Infect Dis 2020; 98: 14-5.
[http://dx.doi.org/10.1016/j.ijid.2020.06.065] [PMID: 32585285]
[106]
Zimet GD, Silverman RD, Fortenberry JD. Coronavirus disease 2019 and vaccination of children and adolescents: prospects and challenges. J Pediatr 2021; 231: 254-8.
[http://dx.doi.org/10.1016/j.jpeds.2020.11.002] [PMID: 33161025]
[107]
U.S. Food and drug administration. Coronavirus (COVID-19) update: FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use
[108]
Jenco M. Pfizer, BioNTech report COVID-19 vaccine safe, highly effective in 12- to 15-year-olds. Available from: https://www.aappublications.org/news/2021/03/31/pfizer-covid19-vaccine-efficacy-adolescents-033121
[109]
Moderna, Inc. Moderna announces first participants dosed in phase 2/3 study of COVID-19 vaccine candidate in pediatric population. Available from: https://investors.modernatx.com/ news-releases/news-release-details/moderna-announces-first-participants-dosed-phase-23-study-0
[110]
Johnson & Johnson Available from: https://www.jnj.com/johnson-johnson-expands-phase-2a-clinical-trial-of-covid-19-vaccine-candidate-to-include-adolescents
[111]
Fricke-Galindo I, Falfán-Valencia R. Genetics insight for COVID-19 susceptibility and severity: a review. Front Immunol 2021; 12: 622176.
[http://dx.doi.org/10.3389/fimmu.2021.622176] [PMID: 33868239]
[112]
Goodson-Gregg FJ, Krepel SA, Anderson SK. Tuning of human NK cells by endogenous HLA-C expression. Immunogenetics 2020; 72(4): 205-15.
[http://dx.doi.org/10.1007/s00251-020-01161-x] [PMID: 32219494]
[113]
Nguyen A, David JK, Maden SK, et al. Human leukocyte antigen susceptibility map for severe acute respiratory syndrome coronavirus 2. J Virol 2020; 94(13): e00510-20.
[http://dx.doi.org/10.1128/JVI.00510-20] [PMID: 32303592]
[114]
Lin M, Tseng H-K, Trejaut JA, et al. Association of HLA class I with severe acute respiratory syndrome coronavirus infection. BMC Med Genet 2003; 4(1): 9.
[http://dx.doi.org/10.1186/1471-2350-4-9] [PMID: 12969506]

Rights & Permissions Print Cite
Article Metrics
28
1
Wayfinder Image
World Prematurity Day
© 2024 Bentham Science Publishers | Privacy Policy